Prophylaxis In Hematopoietic Stem Cell Transplantation Therapeutics
1. Mycamine patent expiration
Treatment: Treatment of esophageal candidiasis and prophylaxis of candida infections in hsct patients; Treatment of patients with candidemia, acute disseminated candidiasis, candida peritonitis and abscesses
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6265536 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Sep, 2015
(10 years ago) | |
| US6107458 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Mar, 2019
(6 years ago) | |
|
US6774104 (Pediatric) | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jul, 2021
(4 years ago) | |
| US6774104 | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jan, 2021
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-821) | Dec 20, 2022 |
| Pediatric Exclusivity(PED) | Jun 20, 2023 |
Drugs and Companies using MICAFUNGIN SODIUM ingredient
Market Authorisation Date: 16 March, 2005
Dosage: INJECTABLE
How can I launch a generic of MYCAMINE before it's drug patent expiration?
More Information on Dosage
MYCAMINE family patents
